Federal Register / Vol. 66, No. 35 / Wednesday, February 21, 2001 / Notices 11033

review, institutions that might

otherwise be subject to the RCR policy

are under no obligation to implement

the policy unless further public notice

is issued in the Federal Register. Any

future PHS action taken to implement

the RCR policy would provide extended

implementation time frames that take

into consideration this suspension.

FOR FURTHER INFORMATION CONTACT:

Barbara Bullman, J.D., Senior Program

Analyst, Division of Education and

Integrity, Office of Research Integrity,

5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5300.

Chris B. Pascal, J.D.,

Director, Office of Research Integrity.

[FR Doc. 01–4226 Filed 2–20–01; 8:45 am]

BILLING CODE 4150–31–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration for Children and

Families

Proposed Information Collection

Activity; Comment Request

Proposed Projects

Title: TANF High Performance Bonus

Report, Assessment of Medicaid and

SCHIP Enrollment.

OMB No.: New Collection.

Description: Public Law 104–93

(PRWORA) established the Temporary

Assistance for Needy Families (TANF)

Program. It also included provisions for

rewarding States that attain the highest

levels of success in achieving the

legislative goals of that program. The

purpose of this collection is to obtain

data upon which to base the

computation for measuring State

performance in meeting those goals by

providing Medicaid and SCHIP work

supports. DHHS will use the

information to allocate the Medicaid/

SCHIP portion of the bonus grant funds

appropriated under the law and

implemented by 45 CFR part 270

published on August 30, 2000. States

will not be required to submit this

information unless they elect to

compete in a Medicaid/SCHIP measure

for the TANF High Performance Bonus

awards in Federal fiscal years 2002 or

2003, or any subsequent Federal fiscal

year for which Congress authorizes and

appropriates bonus funds.

Respondents: Respondents may

include any of the 50 States, the District

of Columbia, and the U.S. Territories of

Guam, Puerto Rico, and the Virgin

Islands.

ANNUAL BURDEN ESTIMATES

Instrument No. of

respondents

No. of

responses

per

respondent

Average

burden

hours per

response

Total

burden

hours

TANF high performance bonus report, assessment of Medicaid and SCHIP enrollment among individuals after leaving TANF assistance ......................................... 54 2 40 4,320

Estimated total annual burden hours ................................................................ ........................ .................... .................... 4,320

In compliance with the requirements

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Administration for Children and

Families is soliciting public comment

on the specific aspects of the

information collection described above.

Copies of the proposed collection of

information can be obtained and

comments may be forwarded by writing

to the Administration for Children and

Families, Office of Information Services,

370 L’Enfant Promenade, SW.,

Washington, DC 20447, Attn: ACF

Reports Clearance Officer. All requests

should be identified by the title of the

information collection.

The Department specifically requests

comments on: (a) Whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency, including

whether the information shall have

practical utility; (b) the accuracy of the

agency’s estimate of the burden of the

proposed collection of information; (c)

the quality, utility, and clarity of the

information to be collected; and (d)

ways to minimize the burden of the

collection of information on

respondents, including through the use

of automated collection techniques or

other forms of information technology.

Consideration will be given to

comments and suggestions submitted

within 60 days of this publication.

Dated: February 14, 2001.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 01–4188 Filed 2–20–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Allergenic Products Advisory

Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting will be closed to the public.

Name of Committee: Allergenic Products

Advisory Committee.

General Function of the Committee: To

provide advice and recommendations to the

agency on FDA’s regulatory issues.

Date and Time: The meeting will be held

on March 5, 2001, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Versailles

Ballrooms I and II, 8120 Wisconsin Ave.,

Bethesda, MD.

Contact: William Freas or Pearline K.

Muckelvene, Center for Biologics Evaluation

and Research (HFM–71), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852, 301–827–0314, or FDA

Advisory Committee Information Line, 1–

800–741–8138 (301–443–0572 in the

Washington, DC area), code 12388. Please

call the Information Line for up-to-date

information on this meeting.

Agenda: On March 5, 2001, the committee

will hear updates on: (1) The Laboratory of

Immunobiochemistry personnel, (2) lot

release statistics, (3) new guidance

documents, (4) research and standardization

programs, and (5) a compliance report. The

committee will discuss whether master seed

stocks of mold strains used for allergenic

extracts should be rederived to reduce a

theoretical risk of transmissible spongiform

encephalopathy transmission. The committee

will also discuss the statistical power of

clinical studies used to assess bioequivalence

as it applies to allergen extract studies. In the

afternoon, the committee will discuss

particulates that appear in allergen extracts

and the effect of these particulates on the

safety and efficacy on these products. In

closed session, the committee will receive a

report on the status of an investigational new

drug application and product license

application supplement.

Procedure: On March 5, 2001, from 8:30

a.m. to 3:30 p.m., the meeting is open to the